Showing 3731-3740 of 4706 results for "".
- Aesyntix Partners With Sentéhttps://practicaldermatology.com/news/20130125-aesyntix_partners_with_sent/2459626/Aesyntix Physician Network (APN), a group purchasing organization and subsidiary of Aesyntix Health, Inc., entered into an agreement with Senté, Inc., a privately held cosmeceutical company that develops differentiated medical skincare pro
- ARTAS System Adopted by Minneapolis Surgeonhttps://practicaldermatology.com/news/20121204-artas_system_adopted_by_minneapolis_surgeon/2459664/Restoration Robotics, Inc. announced the first use of its revolutionary ARTAS System in Minneapolis by Dr. Ron Shapiro of Shapiro Medical Group. The ARTAS System is the first and only FDA-cleared, physician-controlled, computer-assisted technolo
- Ellman International Acquires Four Low-cost Lasers from Sandstonehttps://practicaldermatology.com/news/20120720-ellman_international_acquires_four_low-cost_lasers_from_sandstone/2459768/Ellman International, Inc. has acquired the assets of Sandstone Medical Technologies, LLC., a recognized leader in the aesthetic laser and IPL technology field. Sandstone's high quality laser and IPL portfolio offers four multifunctional systems, a
- Ulthera Announces Indication for Decolletage in Asiahttps://practicaldermatology.com/news/20120709-ulthera_announces_indication_for_dcolletage_in_asia/2459776/Ulthera, Inc., a global, growth-stage medical device company, announced the commercial availability of the Ulthera System in select Asian countries to non-invasively treat the skin on the chest area, or décolletage. The Ulthera Sys
- Suneva to Acquire Worldwide Rights to Refissa(R)https://practicaldermatology.com/news/20120604-suneva_to_acquire_worldwide_rights_to_refissar/2459789/Suneva Medical , a privately-held aesthetics company, will acquire worldwide rights to Refissa® and its marketed generic equivalent from Spear Pharmaceuticals. The portfolio contains the only tretinoin creams with
- Editorial: Transferrable Loyalty and the State of Our Specialtyhttps://practicaldermatology.com/news/20140806-editorial_transferrable_loyalty_and_the_state_of_our_specialty/2459149/With the ongoing battle between Allergan and Valeant, it is evident that no practicing dermatologist can avoid concerns with the painful and tactical machinations. Long-term representatives have likely already changed their nametags from one company to another and are now pitching the same drugs und
- FDA Takes First Step Toward Expanding Sunscreen Optionshttps://practicaldermatology.com/news/fda-takes-first-step-toward-expanding-sunscreen-options/2484881/The American Academy of Dermatology Association (AADA) released a statement from organization president Susan C. Taylor, MD, FAAD commending the Food and Drug Administration (FDA) for taking its first significant step in more than 20 years toward expanding safe and
- Dr. Darrell Rigel Highlights Advances in Skin Cancer Carehttps://practicaldermatology.com/news/dr-darrell-rigel-highlights-advances-in-skin-cancer-care/2484095/Darrell S. Rigel, MD, MS, provided a comprehensive update on the rapidly evolving landscape of skin cancer diagnosis, treatment, and prognostication at the 2025 Fall Clinical Dermatology Conference. From novel genetic assays to refinements in field therapy and systemic strategies, Dr. Rigel’s tal
- JAK Inhibition, Durable Repigmentation Strategies Among Vitiligo Advanceshttps://practicaldermatology.com/news/jak-inhibition-durable-repigmentation-strategies-among-vitiligo-advances/2484093/Vitiligo has entered a new era of treatment innovation, according to Seemal Desai, MD, FAAD, who presented “Vitiligo Spotlight: A Closer Look at JAK Inhibitors” at the 2025 Fall Clinical Dermatology Conference. Dr. Desai characterized the current moment as a “Renaissance period” in vitilig
- Dr. Michelle Henry Highlights Noninvasive Periorbital Rejuvenationhttps://practicaldermatology.com/news/dr-michelle-henry-highlights-noninvasive-periorbital-rejuvenation/2483904/Understanding facial aging patterns specific to richly pigmented skin and adjusting treatment approaches accordingly, especially as patient preferences shift away from traditional lower eyelid filler, is key in managing periorbital aging in patients with skin of color, Michelle Henry, MD, FAAD, s